Special Issue

Immune Responses to Antibiotic Exposure or Treatment

Message from the Guest Editors

The actions of prokaryotic cell-directed antibiotic agents are generally considered safe in mammalians, including humans. Recent advances in bacteria-specific antibiotic actions have been associated with their direct interference with eukaryotic cellular functions, as well as immunity via diverse molecular actions. Moreover, antibiotic exposure or treatment may cause dysbiotic microbial community changes in the normal microbiota. which can be detrimental or beneficial to mammalian immune systems. Any issues linked to acute and chronic inflammatory, malignant, or immunological diseases that are associated with antibiotic exposure or treatments are also recommended. Furthermore, antibiotic exposure- or treatment-linked changes in microbiota comprise another interesting area that may affect the immune system and other immune-linked adverse outcomes. The present Special Issues deal with antibiotic agent-associated actions in immune responses and their clinical implications in humans and animals. However, antibiotic agents are not limited to antibacterial agents, but can include other diverse types of anti-microbial agents against fungi, protists, or parasitic animals.

Guest Editors

Prof. Dr. Yuseok Moon

Laboratory of Mucosal Exposome and Biomodulation, Department of Integrative Biomedical Sciences, Biomedical Research Institute, Pusan National University, Yangsan 50612, Republic of Korea

Dr. Sik Yoon

Department of Anatomy, College of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

Deadline for manuscript submissions

closed (31 December 2022)



an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/120403

Antibiotics
MDPI, Grosspeteranlage 5

4052 Basel, Switzerland Tel: +41 61 683 77 34 antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 7.3 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

